During the last session, Carisma Therapeutics Inc (NASDAQ:CARM)’s traded shares were 0.52 million, with the beta value of the company hitting 1.53. At the end of the trading day, the stock’s price was $0.45, reflecting an intraday gain of 13.47% or $0.05. The 52-week high for the CARM share is $2.67, that puts it down -493.33 from that peak though still a striking 15.56% gain since the share price plummeted to a 52-week low of $0.38. The company’s market capitalization is $18.71M, and the average trade volume was 375.92K shares over the past three months.
Carisma Therapeutics Inc (CARM) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.50. CARM has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.16.
Carisma Therapeutics Inc (NASDAQ:CARM) trade information
Carisma Therapeutics Inc (CARM) registered a 13.47% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 13.47% in intraday trading to $0.45, hitting a weekly high. The stock’s 5-day price performance is 11.77%, and it has moved by -16.69% in 30 days. Based on these gigs, the overall price performance for the year is -82.76%.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 92.5% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, CARM is trading at a discount of -1233.33% off the target high and -1233.33% off the low.
Carisma Therapeutics Inc (CARM) estimates and forecasts
In the rating firms’ projections, revenue will increase 43.48% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 5.42M as predicted by 4 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 4.69M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 4.29M and 3.4M respectively. In this case, analysts expect current quarter sales to grow by 26.40% and then jump by 38.14% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 24.98%. While earnings are projected to return 53.67% in 2025, the next five years will return 37.91% per annum.
CARM Dividends
Carisma Therapeutics Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Also, the Mutual Funds coming in first place with the largest holdings of Carisma Therapeutics Inc (CARM) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.05 shares. This amounts to just over 2.53 percent of the company’s overall shares, with a $0.47 million market value. The same data shows that the other fund manager holds slightly less at 342.63, or about 0.82% of the stock, which is worth about $0.15 million.
